molmed

Investors

Request submitted for first tranche of share capital increase reserved to Société Générale pursuant to SEF agreement

Request submitted for first tranche of share capital increase reserved to Société Générale pursuant to SEF agreement ▾

Investors

Internal dealing

Internal dealing ▾

Investors

Internal dealing

Internal dealing ▾

Investors

Internal dealing

Internal dealing ▾

Investors

MolMed coordinates a CAR T-cell immunotherapy project awarded a 5.9 million Euro grant by the European Commission

MolMed coordinates a CAR T-cell immunotherapy project awarded a 5.9 million Euro grant by the European Commission ▾

Investors

Outcome of Shareholder's Meeting and subsequent Board of Directors

Outcome of Shareholder's Meeting and subsequent Board of Directors ▾

Investors

Results published of a study highlighting the role of memory stem T cells in the treatment of leukaemia Pdf

Results published of a study highlighting the role of memory stem T cells in the treatment of leukaemia Pdf ▾

Investors

Highly promising preclinical data in leukaemia and solid tumours for CAR-CD44v6 presented at ASH

Highly promising preclinical data in leukaemia and solid tumours for CAR-CD44v6 presented at ASH ▾

Investors

MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF Pdf

MolMed files a Conditional Marketing Authorisation in the European Union for NGR-hTNF Pdf ▾

Investors

MolMed and Megapharm enter into a term sheet to commercialise Zalmoxis® in Israel

MolMed and Megapharm enter into a term sheet to commercialise Zalmoxis® in Israel ▾

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.